245 related articles for article (PubMed ID: 10420071)
1. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
3. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
5. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Hoppensteadt DA; Walenga JM; Fasanella A; Jeske W; Fareed J
Thromb Res; 1995 Jan; 77(2):175-85. PubMed ID: 7740509
[TBL] [Abstract][Full Text] [Related]
6. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
7. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor release induced by defibrotide and heparins.
Cella G; Sbarai A; Mazzaro G; Motta G; Carraro P; Andreozzi GM; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2001 Jul; 7(3):225-8. PubMed ID: 11441984
[TBL] [Abstract][Full Text] [Related]
9. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
Hoppensteadt DA; Jeske W; Fareed J; Nicolaides AN
Int Angiol; 1996 Mar; 15(1):39-46. PubMed ID: 8739535
[TBL] [Abstract][Full Text] [Related]
10. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
11. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.
Hansen JB; Svensson B; Olsen R; Ezban M; Osterud B; Paulssen RH
Thromb Haemost; 2000 Jun; 83(6):937-43. PubMed ID: 10896252
[TBL] [Abstract][Full Text] [Related]
12. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
13. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Li Y; Rodriquez M; Spencer FA; Becker RC
J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
[TBL] [Abstract][Full Text] [Related]
15. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
Sandset PM; Bendz B; Hansen JB
Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
[TBL] [Abstract][Full Text] [Related]
16. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
18. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Bates SM; Greer IA; Hirsh J; Ginsberg JS
Chest; 2004 Sep; 126(3 Suppl):627S-644S. PubMed ID: 15383488
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
20. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.
Lupu C; Poulsen E; Roquefeuil S; Westmuckett AD; Kakkar VV; Lupu F
Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2251-62. PubMed ID: 10479670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
